ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Phase 2

Actelion

Ponesimod